entertainment -WSS

entertainment

author：focus 2025-09-28 02:32:47 - browse：257

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： How the messy conversation about Dolly changed bioethics

WSS

Diagnostic tests are hitting their mathematical limits

Patients, doctors press FTC to beef up hospital merger scrutiny

Patients, doctors press FTC to beef up hospital merger scrutiny

Midwives could help bridge maternal health disparities in the U.S.

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

People with substance use disorder deserve online privacy

Wikipedia

entertainment

leisure time

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Diagnostic tests are hitting their mathematical limits

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Chamber of Commerce, DOJ clash in court over drug prices

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

Peter Hotez and the public health issue of online harassment

David Liu startup to focus on CRISPR delivery

Guidelines to prevent youth baseball injuries need more muscle

'A game

entertainment

Why the drug industry's warnings on the IRA's impact fall short

ReNAgade cuts staff seven months after raising $300 million

Patients, doctors press FTC to beef up hospital merger scrutiny

ReNAgade cuts staff seven months after raising $300 million

Chamber of Commerce, DOJ clash in court over drug prices

Will the market for weight loss drugs really reach $100 billion?

Wikipedia

explore

entertainment

knowledge